CytoMed Financial Statements From 2010 to 2025

GDTC Stock   2.67  0.07  2.69%   
CytoMed Therapeutics financial statements provide useful quarterly and yearly information to potential CytoMed Therapeutics Limited investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on CytoMed Therapeutics financial statements helps investors assess CytoMed Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting CytoMed Therapeutics' valuation are summarized below:
Gross Profit
355.2 K
Market Capitalization
26.2 M
Revenue
447.7 K
Earnings Share
(0.22)
Quarterly Revenue Growth
(0.21)
We have found one hundred twenty available fundamental signals for CytoMed Therapeutics Limited, which can be analyzed and compared to other ratios and to its rivals. Investors should ensure to validate all of CytoMed Therapeutics' prevailing performance against the performance from 2010 to 2025 to make sure the company is sustainable down the road. The current year's Working Capital is expected to grow to about (1.4 M). In addition to that, Enterprise Value is expected to decline to about 24.5 M

CytoMed Therapeutics Total Revenue

189,749

Check CytoMed Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among CytoMed Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 66.2 K, Other Operating Expenses of 3.9 M or Research Development of 994 K, as well as many indicators such as Price To Sales Ratio of 317, Dividend Yield of 0.0 or PTB Ratio of 6.7. CytoMed financial statements analysis is a perfect complement when working with CytoMed Therapeutics Valuation or Volatility modules.
  
Check out the analysis of CytoMed Therapeutics Correlation against competitors.

CytoMed Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets14.9 M14.2 M5.1 M
Slightly volatile
Short and Long Term Debt Total489.5 K515.2 K991.1 K
Slightly volatile
Other Current Liabilities411.8 K740.2 K371.8 K
Slightly volatile
Total Current Liabilities783.3 K824.5 K836.3 K
Slightly volatile
Total Stockholder Equity10.3 M9.8 M3.2 M
Slightly volatile
Net Tangible Assets485.8 K511.4 K1.5 M
Slightly volatile
Property Plant And Equipment Net1.5 M1.4 M2.1 M
Slightly volatile
Accounts Payable21.2 K28.3 K16.1 K
Slightly volatile
Cash10.9 M10.3 M2.4 M
Slightly volatile
Non Current Assets Total2.3 M2.6 M2.3 M
Pretty Stable
Cash And Short Term Investments10.9 M10.3 M2.4 M
Slightly volatile
Net Receivables247.2 K235.5 K46.5 K
Slightly volatile
Good Will241320329
Slightly volatile
Common Stock Shares Outstanding8.1 M12.2 M6.7 M
Slightly volatile
Short Term Investments30 K43 K63.5 K
Slightly volatile
Liabilities And Stockholders Equity14.9 M14.2 M5.1 M
Slightly volatile
Non Current Liabilities Total361.6 K367 K538.4 K
Slightly volatile
Other Current Assets688.6 KM326.4 K
Slightly volatile
Total Liabilities2.3 M1.3 M1.5 M
Slightly volatile
Total Current Assets12.2 M11.6 M2.8 M
Slightly volatile
Short Term Debt44 K46.3 K441.4 K
Slightly volatile
Intangible Assets19 K10.9 K29.4 K
Slightly volatile
Common Stock21.7 M20.7 M6.5 M
Slightly volatile
Property Plant Equipment2.6 M2.8 M2.4 M
Slightly volatile
Current Deferred Revenue7.1 K9.7 K5.6 K
Slightly volatile
Long Term Debt401.3 K367 K542.6 K
Slightly volatile
Capital Lease Obligations5.4 K5.7 K24.8 K
Slightly volatile
Net Invested Capital7.1 M13.4 MM
Slightly volatile
Property Plant And Equipment Gross3.6 M3.9 MM
Slightly volatile
Short and Long Term Debt29 K30.5 KM
Slightly volatile
Capital Stock28.6 M27.3 M8.4 M
Slightly volatile

CytoMed Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization66.2 K69.7 K171.6 K
Slightly volatile
Other Operating Expenses3.9 M3.7 M1.4 M
Slightly volatile
Research Development994 K1.4 M763.8 K
Slightly volatile
Total Operating Expenses3.8 M3.6 M1.4 M
Slightly volatile
Interest Expense62.2 K46.2 K76 K
Slightly volatile
Selling General Administrative366.7 K395.9 K201.2 K
Slightly volatile
Selling And Marketing Expenses30.5 K29 K10.2 K
Slightly volatile
Total Revenue189.7 K334.1 K103.9 K
Slightly volatile
Gross Profit165 K245.1 K89 K
Slightly volatile
Cost Of Revenue93.5 K89.1 K19.2 K
Slightly volatile
Reconciled Depreciation384 K438.3 K321.5 K
Slightly volatile
Minority Interest263315212
Slightly volatile

CytoMed Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow1.1 M1.4 MM
Pretty Stable
Depreciation268.9 K331 K213.7 K
Slightly volatile
Other Non Cash Items191.5 K201.5 K190 K
Slightly volatile
Capital Expenditures37.1 K39.1 K802.7 K
Slightly volatile
Total Cash From Financing Activities10 M9.5 M2.8 M
Slightly volatile
End Period Cash Flow5.7 M5.4 M1.4 M
Slightly volatile
Change To Netincome1.5 M1.4 M419 K
Slightly volatile
Change To Liabilities177.3 K293.3 K112.7 K
Slightly volatile
Issuance Of Capital Stock13.7 M13 M2.9 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio317206433
Slightly volatile
PTB Ratio6.77.0520.6114
Pretty Stable
Days Sales Outstanding243231101
Slightly volatile
Book Value Per Share1.00.950.3715
Slightly volatile
Invested Capital667.4 K702.6 K1.5 M
Slightly volatile
Average Payables15.2 K16 K14 K
Slightly volatile
Capex To Depreciation0.160.174.4058
Slightly volatile
PB Ratio6.77.0520.6114
Pretty Stable
EV To Sales322172454
Slightly volatile
Inventory Turnover0.01560.01740.0177
Slightly volatile
Days Of Inventory On Hand23.5 K21.7 K21.7 K
Slightly volatile
Payables Turnover2.972.830.7694
Slightly volatile
Sales General And Administrative To Revenue1.291.362.383
Slightly volatile
Average Inventory189.3 K192.6 K150.7 K
Slightly volatile
Research And Ddevelopement To Revenue4.534.7713.7019
Slightly volatile
Capex To Revenue0.160.173.4965
Slightly volatile
Cash Per Share0.80.770.2227
Slightly volatile
Days Payables Outstanding1271331.4 K
Pretty Stable
Income Quality0.530.750.7056
Slightly volatile
Tangible Asset Value460.6 K484.8 K1.1 M
Slightly volatile
Intangibles To Total Assets0.00110.00120.0092
Slightly volatile
Current Ratio13.3112.673.5559
Slightly volatile
Tangible Book Value Per Share1.00.950.3678
Slightly volatile
Receivables Turnover1.551.635.4279
Very volatile
Shareholders Equity Per Share0.750.720.3254
Slightly volatile
Debt To Equity0.04510.04751.1437
Pretty Stable
Capex Per Share0.00450.00470.082
Slightly volatile
Average Receivables117 K111.4 K27 K
Slightly volatile
Revenue Per Share0.01620.02460.0124
Slightly volatile
Interest Debt Per Share0.0460.04850.136
Pretty Stable
Debt To Assets0.03960.04170.2818
Very volatile
Operating Cycle28129617.5 K
Slightly volatile
Price Book Value Ratio6.77.0520.6114
Pretty Stable
Days Of Payables Outstanding1271331.4 K
Pretty Stable
Ebt Per Ebit1.020.971.1105
Pretty Stable
Company Equity Multiplier1.251.312.4055
Slightly volatile
Long Term Debt To Capitalization0.05010.05270.236
Pretty Stable
Total Debt To Capitalization0.05470.05760.3139
Very volatile
Debt Equity Ratio0.04510.04751.1437
Pretty Stable
Quick Ratio13.3112.673.4527
Slightly volatile
Net Income Per E B T1.121.151.0424
Slightly volatile
Cash Ratio11.8611.292.9498
Slightly volatile
Cash Conversion Cycle15416216.1 K
Slightly volatile
Days Of Inventory Outstanding23.5 K21.7 K21.7 K
Slightly volatile
Days Of Sales Outstanding243231101
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.731.172.2754
Slightly volatile
Price To Book Ratio6.77.0520.6114
Pretty Stable
Fixed Asset Turnover0.180.170.0633
Slightly volatile
Debt Ratio0.03960.04170.2818
Very volatile
Price Sales Ratio317206433
Slightly volatile
Asset Turnover0.02550.02110.0206
Slightly volatile
Gross Profit Margin0.990.840.9158
Pretty Stable
Price Fair Value6.77.0520.6114
Pretty Stable

CytoMed Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap41.7 M46.9 M51.1 M
Slightly volatile
Enterprise Value24.5 M39.2 M26.2 M
Slightly volatile

CytoMed Fundamental Market Drivers

Cash And Short Term InvestmentsM

CytoMed Upcoming Events

6th of May 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About CytoMed Therapeutics Financial Statements

CytoMed Therapeutics stakeholders use historical fundamental indicators, such as CytoMed Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although CytoMed Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in CytoMed Therapeutics' assets and liabilities are reflected in the revenues and expenses on CytoMed Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in CytoMed Therapeutics Limited. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue9.7 K7.1 K
Total Revenue334.1 K189.7 K
Cost Of Revenue89.1 K93.5 K
Sales General And Administrative To Revenue 1.36  1.29 
Research And Ddevelopement To Revenue 4.77  4.53 
Capex To Revenue 0.17  0.16 
Revenue Per Share 0.02  0.02 
Ebit Per Revenue(9.02)(9.47)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether CytoMed Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of CytoMed Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cytomed Therapeutics Limited Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cytomed Therapeutics Limited Stock:
Check out the analysis of CytoMed Therapeutics Correlation against competitors.
You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CytoMed Therapeutics. If investors know CytoMed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CytoMed Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.22)
Revenue Per Share
0.039
Quarterly Revenue Growth
(0.21)
Return On Assets
(0.17)
Return On Equity
(0.26)
The market value of CytoMed Therapeutics is measured differently than its book value, which is the value of CytoMed that is recorded on the company's balance sheet. Investors also form their own opinion of CytoMed Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CytoMed Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CytoMed Therapeutics' market value can be influenced by many factors that don't directly affect CytoMed Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CytoMed Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if CytoMed Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CytoMed Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.